Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.
Urabrelimab, also known as SRF231, is an investigational human monoclonal antibody targeting the CD47 protein, a cell surface antigen involved in immune evasion by cancer cells. The CD47 gene encodes a transmembrane glycoprotein broadly expressed on the surface of various cell types. Functionally, CD47 serves as a "marker of self" by binding to the Signal-regulatory protein alpha (SIRP alpha) receptor on myeloid cells, thereby preventing macrophage-mediated phagocytosis. This interaction is crucial in maintaining homeostasis by inhibiting the immune system from attacking healthy cells. However, CD47 is significantly overexpressed on the surface of many tumor cells, providing a mechanism for these cells to evade the immune system. As such, CD47 is a prominent target in cancer immunotherapy aimed at blocking this "don't eat me" signal to enhance the phagocytosis of cancer cells and improve patient prognosis.
仅用于科研。不用于诊断过程。未经明确授权不得转售。